Tenderwize
Retour à la recherche

Accord de remise non exclusif pour bétaméthasone et calcipotriol

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Feb 26, 2028 · 462 days left·Open·Supplies·Framework
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Betamethason und Calcipotriol in allen Darreichungsformen, ausgenommen Salben und Gele (ATC-Code: D05AX22).

56/100

Score d'opportunité

Needs reviewHigh complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

56 / 100

Complexité

68 / 100

Facteurs de risque

Participation is limited to pharmaceutical entrepreneurs meeting the statutory requirements for the medicines offered;...

The notice provides no estimated value, volumes, reimbursement assumptions or guaranteed purchases, and non-exclusive p...

No procurement documents available

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Niedersachsen. Die Gesundheitskasse.
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Feb 26, 2028

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Supply or commercial provision of medicines containing the active-substance combination betamethasone and calcipotriol, ATC D05AX22, in all dosage forms except ointments and gels.
  • Conclusion of a non-exclusive rebate agreement with AOK Niedersachsen under section 130a(8) SGB V.
Afficher le résumé complet

Non-exclusive open-house rebate agreement for pharmaceutical companies supplying medicines containing betamethasone and calcipotriol in all dosage forms except ointments and gels (ATC D05AX22). AOK Niedersachsen intends to offer uniform contract terms to all interested eligible pharmaceutical entrepreneurs without a selection decision. The arrangement may be replaced by exclusive rebate contracts, which would automatically terminate the open-house agreements. The initial 1 May 2026 accession deadline has passed based on the current date; later accessions are possible until the stated final deadline, subject to the contractual lead time and documents.

Risques

Participation is limited to pharmaceutical entrepreneurs meeting the statutory requirements for the medicines offered;...

The notice provides no estimated value, volumes, reimbursement assumptions or guaranteed purchases, and non-exclusive p...

No procurement documents available

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The participant must be a pharmaceutical entrepreneur within the meaning of section 4(18) AMG, or a contractual association of pharmaceutical entrepreneurs, in relation to the...
  • A medicine may be placed on the market within the AMG scope only by a pharmaceutical entrepreneur established in Germany, another EU Member State or another EEA contracting state.
  • A local representative may participate only if it is itself a pharmaceutical entrepreneur within the statutory meaning for the medicines offered.

Acheteur

Localisation

Hannover, DEU

Identifiant

AOK- Niedersachsen. Die Gesundheitskasse

Activité

Health

Lots (1)

LOT-0000

Betamethasone and Calcipotriol Pharmaceutical Rebate Agreement

Non-exclusive rebate agreement under section 130a(8) SGB V for medicines containing betamethasone and calcipotriol in all dosage forms except ointments and gels, ATC D05AX22. The open-house model permits contract conclusion with all interested eligible pharmaceutical companies on identical terms. Contracts may begin on the first day of a month, last no longer than 24 months, and end no later than 30 April 2028. Lot information is based on structured data and the extracted XML notice.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE929, Germany

Durée

Apr 2026 - Apr 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 26, 2028

Détails de la procédure

Date de publication
18 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
189625-2026

Appels d'offres similaires

Cookies & Privacy

With your consent, we use Google Analytics, Microsoft Clarity (session recordings) and Google Ads cookies to understand how Tenderwize is used and to measure our advertising. You can change your choice at any time via “Cookie Settings” in the footer. Cookie Policy · Privacy Policy